

ASX ANNOUNCEMENT

CELLMID'S EVOLIS PATENT TO BE GRANTED IN CHINA

- The Chinese Patent Office issued notification to grant the application protecting the technology of the évolis® formulations
- Key milestone in the Company's strategy for establishing and protecting évolis® in China
- Increasing commercial value of the évolis® brand beyond sales

SYDNEY, Tuesday, 4 February 2020: Cellmid Limited (ASX: CDY) is pleased to advise that the Chinese Patent Office has issued a notice of intention to grant in relation to Application No 201480073162.6 entitled "Method of Treatment of Alopecia with Monoterpenoids". The patent expires in December 2034.

The Chinese patent provides protection in the territory for hair therapy formulations comprising a class of small molecules called monoterpenoids, originally derived from botanical extracts.

Granting of this patent in China is an important commercial milestone for the Company's Chinese product strategy. It provides broad protection of the FGF5 technology and several ingredients adding value to the Company's asset portfolio.

With improved protection at formulation and brand level, the patent adds to the product security along with the YPB consumer protection technology (ASX announcement, 28 November 2017), the licensed 'Australian Made' logo and the registered evolis® trademarks.

The imminent granting of this patent comes at a key time in the expansion of the Company's distribution into China following from the announcement of the Cross Border e-commerce Partnership with Aeon international (ASX announcement, 1 October 2019), and the agreement with Fukangren to register the products with the SFDA and sell the products in Chinese Pharmacies and clinics (ASX announcement, 2 May 2018).

Background The method covered by this patent involves administering a topical formulation containing a monoterpenoid to inhibit the hair growth cycle regulatory protein fibroblast growth factor 5 (FGF5). Detailed scientific studies have shown that FGF5 activity in hair follicles is associated with disruption of the hair cycle, leading to withdrawal from the growth or anagen phase and entry into the regressive catagen phase, followed by follicle rest and hair loss.

Rigorous testing of various monoterpenoid compounds by the Advangen Hair Gene Research Laboratory in Tokyo, Japan, showed that several were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the anagen phase (ASX announcement, 2 March 2017).



Topical application of formulations containing key botanical extracts and FGF5-inhibiting monoterpenoids is central to Advangen's évolis® products against hair loss. The évolis® products containing monoterpenoid compounds have been shown to reduce hair loss and increase the number of actively growing follicles in a blinded, placebo controlled clinical study (published in the journal Clinical, Cosmetic, and Investigational Dermatology (2017) 10: 71-85).

The monoterpenoids-alopecia patents are held by Cellmid's wholly owned subsidiary, Advangen Limited. They protect the formulation of and distinguish the évolis® therapeutic and anti-aging hair care ranges from any other product on the market.

Approved for release by the Board of Directors.

End
Contact:
Maria Halasz, CEO
T+612 9221 6830

@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and <a href="https://www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Lyramid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.